Observational studyProstate cancer and prostatic diseases2020
Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland.
Observational study in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS.Scientific reports · 2021Trial
- Preclinical animal models of lower urinary tract dysfunction associated with metabolic syndrome.Nature reviews. Urology · 2026Review
- Association between dynamic abdominal obesity (DAO) and benign prostatic hyperplasia (lower urinary tract symptoms): evidence from the China Health and Retirement Longitudinal Study (CHARLS).World journal of urology · 2026Article
- SRD5A2 and emerging therapies in androgen-driven disorders.Nature reviews. Urology · 2026Review
- The Positive Association Between RCII and Endometriosis and Its Integration into a Clinical Predictive Model: A Cross-Sectional Study.International journal of women's health · 2026Article
- Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.International journal of nanomedicine · 2026Review
- Using interpretable machine learning model to predict lymph node metastasis in patients with localized prostate cancer.Frontiers in oncology · 2026Article
- Sex- and Ethnic-Specific Associations of Serum Lipids with Risk of 12 Cancers: Findings from 506,381 Adults in Two Large Cohorts.Antioxidants (Basel, Switzerland) · 2025Article
- The Impact of Obesity on Prostate Cancer and Progression to Castration Resistance-Real-World Data from a Romanian Center.Journal of clinical medicine · 2025Article
- The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy:a review.Frontiers in oncology · 2025Review
- Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.Chinese journal of integrative medicine · 2025Review
- Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.Frontiers of medicine · 2024Review
- Zhuangyao Jianshen pill ameliorates testosterone-induced benign postatic hyperplasia in rats.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
- Enhanced prostatic Esr1The Journal of pathology · 2024Article
- Sex steroid hormone residues in milk and their potential risks for breast and prostate cancer.Frontiers in nutrition · 2024Review
- Exploring the Enigma of 5-ARIs Resistance in Benign Prostatic Hyperplasia: Paving the Path for Personalized Medicine.Current urology reports · 2023Review
- Decoding the Influence of Obesity on Prostate Cancer and Its Transgenerational Impact.Nutrients · 2023Review
- Steroid hormone imbalance drives macrophage infiltration and Spp1/osteopontinThe Journal of pathology · 2023Article
- Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia.BMC urology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
objectiveOur patient cohort revealed that obesity is strongly associated with steroid-5α reductase type 2 (SRD5A2) promoter methylation and reduced protein expression. The underlying mechanism of prostatic growth in this population is poorly understood. Here we addressed the question of how obesity, inflammation, and steroid hormones affect the development of benign prostatic hyperplasia (BPH). MATERIAL AND
methodsWe used preadipocytes, macrophages, primary human prostatic stromal cells, prostate tissues from high-fat diet-induced obese mice, and 35 prostate specimens that were collected from patients who underwent transurethral resection of the prostate (TURP). RNA was isolated and quantified with RT-PCR. Genome DNA was extracted and SRD5A2 promoter methylation was determined. Sex hormones were determined by high-performance liquid chromatography-tandem mass spectrometry. Protein was extracted and determined by ELISA test.
resultsIn prostatic tissues with obesity, the levels of inflammatory mediators were elevated. SRD5A2 promoter methylation was promoted, but SRD5A2 expression was inhibited. Inflammatory mediators and saturated fatty acid synergistically regulated aromatase activity. Obesity promoted an androgenic to estrogenic switch in the prostate.
conclusionsOur findings suggest that obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland, which may serve as an effective strategy for alternative therapies for management of lower urinary tract symptoms associated with BPH in select individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.